[8-K] Emergent BioSolutions Inc. Reports Material Event

Rhea-AI Filing Summary

Emergent BioSolutions (EBS) furnished its quarterly results update. The company announced financial and operating results for the quarter ended September 30, 2025 via a press release, and scheduled a conference call on October 29, 2025 to discuss the quarter. The press release is furnished as Exhibit 99.1 and the earnings call presentation as Exhibit 99.2.

The materials in Items 2.02 and 7.01 and Exhibits 99.1 and 99.2 are furnished, not filed, under the Exchange Act. The company noted the call slides would be posted on its website.

0001367644false00013676442025-10-292025-10-29

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 29, 2025

EMERGENT BIOSOLUTIONS INC.

(Exact name of registrant as specified in its charter)

Delaware

001-33137

14-1902018

(State or other jurisdiction

(Commission File Number)

(IRS Employer

of incorporation)

Identification No.)

 300 Professional Drive,

Gaithersburg, Maryland 20879

(Address of principal executive offices, including zip code)

(240) 631-3200

(Registrant’s telephone number, including area code)

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐   Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) 

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) 

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class			Trading Symbol(s)			Name of each exchange on which registered
Common Stock, $0.001 par value per share			EBS			New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company     ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02. Results of Operations and Financial Condition.

On October 29, 2025, Emergent BioSolutions Inc. (the "Company") issued a press release (the "Press Release") announcing its financial and operating results for the quarter ended September 30, 2025. A copy of the Press Release is furnished as Exhibit 99.1 to this Current Report on Form 8-K (this "Form 8-K") and is incorporated herein by reference.

Item 7.01. Regulation FD Disclosure.

On October 29, 2025, the Company will host a conference call to discuss its financial and operating results for the quarter ended September 30, 2025. The Company will use presentation materials in connection with this conference call (the "Earnings Call Slides"), which will be posted on the Company’s website at www.emergentbiosolutions.com. A copy of the Earnings Call Slides is furnished as Exhibit 99.2 to this Form 8-K and is incorporated herein by reference. Information on the Company's website is not, and will not be deemed to be, a part of this Form 8-K or incorporated into any other filings the Company may make with the U.S. Securities and Exchange Commission.

The information contained in Items 2.02 and 7.01 of this Form 8-K and Exhibits 99.1 and 99.2 attached hereto, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise be subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.						Description
99.1						Press release issued by Emergent BioSolutions Inc. on October 29, 2025.
99.2						Earnings Call Slides, dated October 29, 2025.
104						Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

			EMERGENT BIOSOLUTIONS INC.
Dated: October 29, 2025			By:			/s/ RICHARD S. LINDAHL
						Name: Richard S. Lindahl Title: Executive Vice President, Chief Financial               Officer and Treasurer

FAQ

What did Emergent BioSolutions (EBS) announce in this 8-K?

It furnished financial and operating results for the quarter ended September 30, 2025, with a press release (Exhibit 99.1) and earnings call slides (Exhibit 99.2).

When is Emergent BioSolutions’ conference call for Q3 2025?

The company will host a conference call on October 29, 2025 to discuss quarterly results.

Where can I find the press release and slides for EBS’s Q3 2025 results?

The press release is Exhibit 99.1 and the earnings call slides are Exhibit 99.2; slides will also be posted on the company’s website.

Are the Q3 2025 materials considered filed with the SEC?

No. The information in Items 2.02 and 7.01 and Exhibits 99.1 and 99.2 is furnished, not filed, under the Exchange Act.

Which 8-K items does this report include for EBS?

Item 2.02 (Results of Operations and Financial Condition) and Item 7.01 (Regulation FD Disclosure).

What is the period covered by Emergent BioSolutions’ results?

The results are for the quarter ended September 30, 2025.